Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Master Protocol for squamous cell lung cancer readies for launch

Nature Biotechnology volume 32, pages 116–117 (2014)Cite this article

Subjects

This article has been updated

The master protocol is a “truly exciting development, one that will benefit industry and patients,” says US Food and Drug Administration (FDA) Commissioner Margaret Hamburg. “It vastly increases the chances of finding more and better treatments.” Although a concept paper from several years ago laid the groundwork, the practical genesis of the master protocol was a brainstorming session early during 2012, according to oncologist David Gandara of the University of Davis, California, part of the steering committee whose members worked out details for the protocol. “We concluded the classic drug development paradigm needed to be revised because it takes seven and a half years to complete and has too many failures,” he says.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Change history

  • 29 May 2014

    In the version of this article initially published, Genentech's compound Taselisib was incorrectly labeled as Pictilisib in Table 1. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. Washington, DC

    Jeffrey L Fox

Authors
  1. Jeffrey L Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fox, J. Master Protocol for squamous cell lung cancer readies for launch. Nat Biotechnol 32, 116–117 (2014). https://doi.org/10.1038/nbt0214-116b

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0214-116b

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing